NEW YORK (GenomeWeb News) - Meridian Bioscience today reported $44.8 million in preliminary revenue for its fiscal first quarter, marking a 1 percent decline from the year-ago period and falling short of consensus analyst estimates of $49 million.

The company attributed the disappointing results to several factors, including reduced hospital admissions, declining C. difficile incidence rates, shipment delays in its Life Science business, timing of the start of the influenza season, and food test ordering patterns.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.